Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
Saved in:
| Title: | Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB. |
|---|---|
| Authors: | Jamalian S; Genentech, Inc., South San Francisco, California, USA., Dolton M; Roche Products Australia Pty Ltd., Sydney, New South Wales, Australia., Chanu P; Genentech/Roche, Lyon, France., Ramakrishnan V; Genentech, Inc., South San Francisco, California, USA., Franco Y; Genentech, Inc., South San Francisco, California, USA., Wildsmith K; Genentech, Inc., South San Francisco, California, USA., Manser P; Genentech, Inc., South San Francisco, California, USA., Teng E; Genentech, Inc., South San Francisco, California, USA., Jin JY; Genentech, Inc., South San Francisco, California, USA., Quartino A; Genentech, Inc., South San Francisco, California, USA., Hsu JC; Genentech, Inc., South San Francisco, California, USA. |
| Corporate Authors: | Alzheimer's Disease Neuroimaging Initiative |
| Source: | CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jul; Vol. 12 (7), pp. 1029-1042. Date of Electronic Publication: 2023 May 02. |
| Publication Type: | Observational Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
